IVIEW Therapeutics Inc
Long-acting in-situ gel nasal spray combining povidone iodine and budesonide for chronic rhinosinusitis treatment
- Sector
- Medtech
- Headquarters
- Cranbury, NJ
- Latest Form D
- $715K, May 2024
- Total capital
- $9.5M
- Federal grants
- $1.8M
- 6 awards · 2016–2019
- Rank in peer group#15 of 445
- Private capital raised
- $7.7M
- 2 Form D · last May 2024
- 29 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 9
- 22 pending · first 2022
- Rank in peer group#22 of 445
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$715K
- Private capital raisedForm D · SEC · 1st filing$7M
- Federal grantHealth and Human S · Phase I · In-situ gel of Povidone Iodine/Budesonide as Sustained Nasal Drug Delivery for the Treatment of Chronic Rhinosinusitis$300K
- Federal grantHealth and Human S · Phase I · In-situ gel of Povidone Iodine/Budesonide as Sustained Nasal Drug Delivery for the Treatment of Chronic Rhinosinusitis$580K
- Federal grantHealth and Human S · Phase I · In-situ gel of Povidone Iodine/Budesonide as Sustained Nasal Drug Delivery for the Treatment of Chronic Rhinosinusitis$280K
- Federal grantHealth and Human S · Phase I · Novel Extended Release Povidone Iodine Ophthalmic Drop for Viral Conjunctivitis$25K
- Federal grantHealth and Human S · Phase I · Novel Extended Release Povidone Iodine Ophthalmic Drop for Viral Conjunctivitis$323K
Show 1 earlier federal award
- Federal grantHealth and Human S · Phase I · Novel Extended Release Povidone Iodine Ophthalmic Drop for Viral Conjunctivitis$298K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
55months
from IVIEW Therapeutics Inc’s first federal award to its first private round.
- First federal award · Aug 2016
- Health and Human S · $298K
- First Form D · Mar 2021
- $7M · 1st Form D
- Awards before first raise
- 6 awards
An association in public records, not a cause or a prediction.
Standing among 445 peers
Line = medianMedtech · Device
- Federal grants#15 · top 3%
- Granted patents#22 · top 5%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Bo LiangResearcherExecutive Officer, DirectorLinked by 3 patents · $1.8M in grants as PI
- Bin HeDirectorNamed in SEC Form D filings
- Houman HemmatiExecutive Officer, DirectorNamed in SEC Form D filings
- Jingjie LiDirectorNamed in SEC Form D filings
- John J BaldwinDirectorNamed in SEC Form D filings
- Jun J DuDirectorNamed in SEC Form D filings
Show all 11 people
- Qi ZhuDirectorNamed in SEC Form D filings
- Tao J DuDirectorNamed in SEC Form D filings
- Tom Tao DuDirectorNamed in SEC Form D filings
- Wei WangExecutive Officer, DirectorNamed in SEC Form D filings
- Xiaolu SunDirectorNamed in SEC Form D filings
What it has protected
USPTO · 9 granted of 31- GrantedMethod of treating ocular discomfortUSPTOUS 12,648,955
- GrantedMethod of treating blepharitis or conjunctivitisUSPTOUS 12,599,619
- GrantedStable Pharmaceutical Articles Containing Dilute Povidone Iodine FormulationsUSPTOUS 12,514,873
Show all 31 patent records
- Method of treating ocular discomfortJun 9, 2026 · US 12,648,955Granted
- Method of treating blepharitis or conjunctivitisApr 14, 2026 · US 12,599,619Granted
- Stable Pharmaceutical Articles Containing Dilute Povidone Iodine FormulationsJan 6, 2026 · US 12,514,873Granted
- Treatment of Neuropathic Sensitization DisordersSep 26, 2024 · Application 18260908Pending
- Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfortJul 9, 2024 · US 12,029,743Granted
- Self-complementary AAV vectors carrying dominant negative RhoA and methods of use to treat ocular diseasesMar 28, 2024 · Application 18468299Pending
- Di-isopropyl-phosphinoyl-alkanes (dapa) Compounds As Topical Agents For The Treatment Of Sensory DiscomfortJun 27, 2023 · US 11,684,628Granted
- Pharmaceutical Formulations That Form Gel In SituFeb 14, 2023 · US 11,576,973Granted
- In Situ Gel-Forming Pharmaceutical Compositions and Uses Thereof for Sinus DiseasesJan 10, 2023 · US 11,547,659Granted
- Novel Rapid-deposition Thin-film Forming Compositions As Effective Wound Care TreatmentOct 18, 2022 · US 11,471,481Granted
- Treatment of upper aerodigestive tract disorders and coughAug 9, 2022 · US 11,406,649Granted
- Treatment of airway disorders and coughAug 20, 2020 · Application 16602539Pending
- Methods For Improving Lung Condition And AirwayDec 7, 2017 · Application 15678836Pending
- Method For Reducing Corneal Fluorescein Staining With TRPM8 AgonistsApplication PCTUS2026011149Pending
- Pharmaceutical Formulations That Form Gel In SituApplication PCTUS2016058722Pending
- Novel Eyelid Delivery of Ophthalmic Composition Containing Muscarinic Receptor Modulators for Prevention and Treatment of Ocular DisordersApplication 19519952Pending
- Aqueous Nanomicelle Ophthalmic Formulations Containing DifluprednateApplication 19602111Pending
- Novel Eyelid Delivery Of Ophthalmic Composition Containing Muscarinic Receptor Modulators For Prevention And Treatment Of Ocular DisordersApplication PCTUS2025046579Pending
- Methods for Increasing Stability of Dilute Povidone IodineApplication 19602109Pending
- Delivery Of TRPM8 Agonists To The Ocular Margins For Relief Of Ocular DisordersApplication PCTUS2025028264Pending
- Gel Forming Ophthalmic Compositions Containing Povidone Lodine And SteroidsApplication PCTUS2025025519Pending
- Aqueous Nanomicelle Ophthalmic Formulations Containing DifluprednateApplication PCTUS2023086496Pending
- Methods For Increasing Stability Of Dilute Povidone IodineApplication PCTUS2023086309Pending
- Compounds, Compositions And Methods For Treatment Of Age-related Ocular DisordersApplication PCTUS2023080439Pending
- Self-complementary Aav Vectors Carrying Dominant Negative Rhoa And Methods Of Use To Treat Ocular DiseasesApplication PCTUS2023074351Pending
- Di-isopropyl-phosphinoyl-alkanes As Topical Agents For The Treatment Of Eye DiseasesApplication PCTUS2023020878Pending
- Use Of 1-DI-ISOPROPYL-PHOSPHINOYL-ALKANE Compounds For Treatment Of Ocular DiscomfortApplication PCTUS2022012051Pending
- Treatment Of Neuropathic Sensitization DisordersApplication PCTUS2022011874Pending
- Stable Pharmaceutical Articles Containing Dilute Povidone Iodine FormulationsApplication PCTUS2020041089Pending
- In Situ Gel-forming Pharmaceutical Compositions And Uses Thereof For Sinus DiseasesApplication PCTUS2018049333Pending
- Novel Rapid-deposition Thin-film Forming Compositions As Effective Wound Care TreatmentApplication PCTUS2016069420Pending
Related companies, and why
- Intuitive Biosciences, Inc.Similar federal contract value in Medtech · null in contracts
- Precede BiosciencesSimilar federal contract value in Medtech · null in contracts
- CALVIRI, INC.Similar federal contract value in Medtech · null in contracts
- SENTIAR, INC.Similar federal contract value in Medtech · null in contracts
- ZETAGEN THERAPEUTICS, INC.Similar federal contract value in Medtech · null in contracts
- Harpoon Medical, Inc.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .